Table 3.
Licensing and option agreements.
| Company | Compound | Mode of action/therapeutic area | Status mid‐2016 (highest phase reached) |
|---|---|---|---|
| Dr. Reddy's Laboratories | balaglitazone (DRF‐2593), 1 | PPARγ agonism/diabetes | Licensed to Novo Nordisk (1997–2004); Rheosciences (2005–2010); DRL owns development in 2010, Phase 3—stop 2011 |
| ragaglitazar (DRF‐2725), 2 | Dual PPARα/γ agonism/diabetes | Licensed to Novo Nordisk (1998‐2002), Phase 3—stop 2002 | |
| DRF‐4158 (LBL‐752) | Dual PPARα/γ agonism, HMG‐CoA reductase inhibition/metabolic disorders | Licensed to Novartis (2001), Preclinical—stop 2003 | |
| Ranbaxy | RBx‐2258 (SPM‐969), parvosin, pamirosin, 4 | α1/δ‐Adrenoceptor antagonism/benign prostatic hyperplasia | Licensed to Schwarz Pharma (2002), Phase 2—stop 2004 |
| RBx‐10558, PPD‐10558, 5 | HMG‐CoA synthase inhibition/hypercholesterolemia | Licensed to Furiex Pharma/PPD (2007); Phase 2—stop 2011 | |
| Torrent | TRC‐4186, 8 | AGE breaker/diabetes‐related cardiovascular disorders | Option agreement with Novartis (2002–2005); Phase 2 completed 2015 |
| Glenmark | GRC‐3886 (oglemilast), 23 | PDE‐4 inhibition/asthma, COPD | Licensed to Forest (2004), Teijin (2005), Phase 2—stop 2009 |
| GRC‐6211, 25 | TRPV1 antagonism/pain, migraine, incontinence, asthma | Licensed to Lilly (2007), Phase 2—stop 2008 | |
| GRC‐8200 (melogliptin), 24 | DPP‐IV inhibition/diabetes | Licenced to Merck KGaA (2006), returned 2008, Phase 2—stop 2011 | |
| GRC‐15300 (SAR292833) | TRPV3 antagonism/pain | Licensed to Sanofi (2010), Phase 2—stop 2014 | |
| GRC‐27864 | mPGES‐1 inhibition/inflammation, pain | Option agreement with Forest Labs (2012), Phase 1—ongoing | |
| Orchid | OCID‐5090/AAI101, 30 | β‐lactamase inhibition/bacterial infections | Licensed to Allecra Therapeutics (2013), Phase 1, France—ongoing |
| Jubilant | CK‐103 (JBET‐050) | BET BRD4 bromodomain inhibition/cancer | Licensed to Checkpoint Therapeutics (2016), preclinical—ongoing |
| Aurigene | Debio‐1142 | Kinase inhibition/cancer | Licensed to Debiopharm (2011), preclinical—stop 2014 |
| AUNP‐012 (W014A) | PD‐1 inhibition/cancer | Licensed to Pierre Fabre (2014)—preclinical stop 2015 | |
| ODM‐207 | BET bromodomain inhibition/cancer | Option agreement with Orion Pharma (2014), preclinical—ongoing | |
| CA‐170 (AUPM‐170) | Dual PD‐L1/Vista inhibition/cancer | Licensed to Curis (2015)—preclinical ongoing | |
| CA‐327 (AUMP‐327) | Dual PD‐L1/Tim‐3/cancer | Option agreement with Curis (2015), preclinical—ongoing | |
| CA‐4948 (AU‐4948) | IRAK‐4 inhibition/cancer | Licensed to Curis (2015), preclinical—ongoing | |
| Connexios | CNX‐012‐570 | AMPK activation/diabetes | Licensed to Boehringer Ingelheim (2014), preclinical—ongoing |
| Rhizen | TGR‐1202 (RP5264), 35 | Selective PI3Kδ kinase inhibition/cancer | Licensed to TG Therapeutics (2012), Phase 2/3—ongoing |
| RP‐6503 | Dual PI3Kγ/δ kinase inhibition/asthma, COPD | Licensed to Novartis (2015), preclinical—ongoing | |
| Curadev | RG70099 (CRD1152) | Dual IDO/TDO inhibition/cancer | Licensed to Roche (2015), preclinical—ongoing |